White Paper

Shifting From One Drug For All Patients To Personalized Genomics-Based Therapeutic Options

Source: Q2 Solutions

By Victor Weigman, Ph.D., Associate Director, Translational Genomics and Patrice Hugo, Ph.D., Chief Scientific Officer, Q2 Solutions

Shifting From One Drug For All Patients To Personalized Genomics-Based Therapeutic Options

With advancements in clinical informatics and genomics, there has been a paradigm shift from “one drug fits all” toward precision medicine – taking account of individual variability in genes, environment and lifestyle – across therapeutic areas. Precision medicine allows identification of patients who would likely benefit the most from a treatment and suffer the least side effects. For instance, such screening can reveal genetic makeup likely aligned with the molecular mechanisms of action of a drug, increasing the probability of a patient’s response to the therapy. This helps find better matches for existing and novel drugs, with the goal of ensuring that the right drug is used in the right patient at the right time.

Download this white paper to learn and implement genomics-based strategies to advance your precision medicine clinical outcomes. Discover how a comprehensive personalized genomics strategy can help you identify the patients who would most likely benefit from a treatment and suffer the least side effects, ensuring the right drug is used in the right patient at the right time.